Organization
Renji Hospital Shanghai Jiaotong University School of Medicine
6 abstracts
Abstract
Tumor immune microenvironment analysis and MRI results of a phase II trial investigating tislelizumab (T) in the neoadjuvant treatment of high-risk upper tract urothelial carcinoma (UTUC).Org: Ren Ji Hospital, Renji Hospital Shanghai Jiaotong University School of Medicine,
Abstract
Effect of blocking CD96 on CD8+ T cell–mediated elimination of tumor dormancy.Org: Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital,
Abstract
A propensity score–matched comparison of fruquintinib (FRU) versus FRU combined with PD-1 inhibitors for microsatellite stability (MSS) metastatic colorectal cancer: Real-world data.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Predictive value of positive lymph node ratio in patients with locally advanced gastric remnant cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, Renji Hospital Shanghai Jiaotong University School of Medicine, School of Medicine, Zhejiang University, Hangzhou, China, Shanghai Jiao Tong University Affiliated Sixth People’s Hospital, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
Trophoblast cell-surface antigen 2 is a biomarker and potential therapeutic target in human colon cancer.Org: Department of Oncology and Haematology, Division of Oncology, University Hospital of Modena, Modena, Italy, State Key Laboratory of Systems Medicine for Cancer, Renji Hospital Shanghai Jiaotong University School of Medicine, Shanghai Jiao Tong University School of Medicine, Shanghai, China, Gracell Biotechnologies, Ltd.,
Abstract
A single-center, prospective, single-arm, phase II trial to evaluate the adjuvant efficacy of camrelizumab with docetaxel plus S-1 for stage III (PD-L1+/dMMR/EBV+) gastric cancer after D2 resection.Org: Shanghai Jiaotong University School of Medicine, Renji Hospital Shanghai Jiaotong University School of Medicine,